ADHD

Study findings from Hannover Medical School broaden understanding of attention deficit hyperactivity disorder therapy

ADHD Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"The effect of MPH in adults with ADHD is a question that is often raised, because many adults request such therapy today. As yet, there is a lack of studies on event-related potentials (ERPs) and MPH in ADHD adults. In the present study we examined 10 adults diagnosed with ADHD, with and without MPH medication (30 mg daily), by means of ERP in a visual Go/NoGo experiment to gain information about target evaluation processing in these patients and about the effects on these attentional processes during medication with MPH. Visually, there seem to be differences in the frontal electrodes for the N2 and in the parietal electrodes for the P300. But these differences do not achieve statistical significance. There are also no statistically relevant differences for the N1 or the slow wave. MPH does not seem to have an effect on target evaluation processing, when comparing the ERPs of non-medicated and medicated ADHD adults," wrote M.D. Ohlmeier and colleagues, Hannover Medical School.

The researchers concluded: "Especially the P3 does not appear to be modulated by medication with MPH in these ADHD adults, in contrast to findings in ADHD children."

Ohlmeier and colleagues published their study in Neuroscience Letters (Effects of methylphenidate in ADHD adults on target evaluation processing reflected by event-related potentials. Neuroscience Letters, 2007;424(3):149-54).

For additional information, contact M.D. Ohlmeier, Hannover Medical School (MHH), Dept. of Clinical Psychiatry and Psychotherapy, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.

The publisher's contact information for the journal Neuroscience Letters is: Elsevier Science Ireland Ltd., Customer Relations Manager, Bay 15, Shannon Industrial Estate, Co. Clare, Ireland.

Keywords: Germany, Hannover, Attention Deficit Hyperactivity Disorder Therapy, Adrenergic Agent, Adrenergic Uptake Inhibitor, Attention Deficit Hyperactivity Disorder, Central Nervous System Stimulant, Developmental Disabilities, Dopamine Uptake Inhib, Methylphenidate, Neuroscience, Therapy, Treatment.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.